bih.button.backtotop.text
BROWSE BY TEST NAME
%
1
2
3
5
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Clear
 
Test Code:
090-70-8505

Order Name:
ANA Profile II

 
Useful For:
Diagnosis of a systemic rheumatic disease in the suspected patient.
 
Methodology:
Immunoblot
 
Test List In Profile:
Anti nRNP
Anti Sm
Anti SS-A  
Anti Ro-52
Anti SS-B 
Anti Scl-70 
Anti Jo-1 
Anti Centromere Protein B (CENP B)
Anti dsDNA 
Anti Nucleosomes   
Anti Histones
Anti Ribosomal P-Protein
 
AliasesName:
Anti-Ribonuclear Protein
Autoantibodies to U1RNP
Ribonucleoprotein (RNP) Autoantibodies
Autoantibodies to Sm (Smith)
Sm (Anti-Sm) (Smith)
Sm (Smith) Autoantibodies
Anti-Ro
Anti-Sjogren's Syndrome
Anti-SSA (Anti-Sjogren's Syndrome A)
Autoantibodies to SSA (Ro)
Ro (Anti-SSA)
Anti-La
Anti-SSB (Anti-Sjogren's Syndrome B)
Autoantibodies to SS-B/LA, Serum
La (Anti-SSB)
SSB (Anti-SSB)
ACA (Anticentromere Antibodies)
Anticentromere Antibodies
Centromere Antibodies, IgG
Centromere Autoantibodies
 
 
 
Test Code:
090-70-8505

Order Name:
ANA Profile II

 
Collection Specimen Or Container:
Blood/ Plain blood (Red top) 6 mL, 1 tube
 
Specimen Testing Type:
Serum, minimum volume 0.5 mL
 
Sub Mission Container:
Plastic tube
 
Rejection Criteria:
Hemolysis: Mild OK; Gross reject
Lipemia: Mild OK; Gross reject
Icterus: Mild OK; Gross reject
Other: N/A
 
Specimen Stabillity:
Specimen Type Temperature Time
Serum Refrigerated, 2oC to 8oC 14 days
 
 
 
Test Code:
090-70-8505

Order Name:
ANA Profile II

 
Method detail:
Immunoblot
 
Schedule:
Test daily, at 12:00 p.m.
 
Turnaround Time:
Received specimen to reported within 2 days.
 
Performing Location:
Molecular biology & Genetics, Laboratory Department Tel.14168
 
Specimen Retention Time:
7 days
 
 
 
Test Code:
090-70-8505

Order Name:
ANA Profile II

 
 
Clinical Information:
Antibodies against nuclear antigens (ANA) are directed against various cell nuclear components.  Among the most important nuclear antigens, including cytoplasmic antigens, are nRNP/Sm, Sm, SS-A (Ro), SS-B (La), Scl-70, PM-Scl, Jo-1, centromeres, dsDNA, nucleosomes, histones and ribosomal P-proteins.  They are mainly components of functional nuclear particles, are bound to nucleic acids or fulfil functions in the cell cycle, eg. in transcription or translation.  The investigation of ANA and subsequent differentiation within the ANA or ENA spectrum contributes greatly to establishing a diagnosis, particularly in the following rheumatic diseases:
- Systemic Lupus Erythematosus (SLE)
- Sharp syndrome (mixed connective tissue disease = MCTD)
- Sjogren's Syndrome (SS)
- Systemic Sclerosis (SSc)
- Polymyositis (PM) or Dermatomyositis (DM)
 
Reference Value:
Test: ANA Profile II
 
Tests Reference Value
Anti nRNP Negative
Anti Sm Negative
Anti SS-A Negative
Anti Ro-52 Negative
Anti SS-B Negative
Anti Scl-70 Negative
Anti Jo-1 Negative
Anti Centromere Protein B (CENP B) Negative
Anti dsDNA Negative
Anti Nucleosomes Negative
Anti Histones Negative
Anti Ribosomal P-Protein Negative
 
Interpretation:
The serological detection of autoantibodies against individual or several cell nuclear autoantigens is an essential element in the diagnosis of autoimmune diseases.  The frequency (prevalence) of anti-nuclear antibodies in inflammatory rheumatic diseases in between 20% and 100% (in rheumatoid arthritis between 20% and 40%).  Therefore, differential ANA diagnostics to detect autoantibodies against different nuclear antigens is indispensable for the identification of individual rheumatic diseases. The ANA profiles offer innovative test combination based on the lineblot technology.  Positive test resulst provide important serodiagnostic information for the diagnosis of the rheumatic diseases, as well as further autoimmune disease such as primary biliary liver cholangitis (PBC). However, antibodies against nuclear antigens are detectable in subjectively healthy individuals, usually at a low level.  This finding is more common in women than men and the frequency of a detectable ANA in healthy women over 40 years of age may approach 15% to 20%. ANA may also be detectable following viral illnesses, in chronic infections, or in patients treated with many different medications.  A diagnosis should not be made based on a single test result. The clinical symptoms of the patient should always be taken into account along with the serological results by the physician.  
 
Clinical Reference:
Manufacturer’s reagent package insert, Antibodies against nuclear antigens (IgG) Test instruction for the ANA Profile 1 EUROLINE, March 2018, EUROIMMUN, Lübeck, D-23560 Germany.